Prothena Corp Public (PRTA) Cash & Equivalents (2012 - 2026)
Prothena Corp Public (PRTA) posted quarterly Cash & Equivalents of $329.5 million for Q1 2026, down 21.17% year-over-year from $417.9 million in Q1 2025, and up 7.13% quarter-over-quarter from $307.5 million in Q4 2025.
Prothena Corp Public (PRTA) Cash & Equivalents (2012 - 2026) Analysis & Trends
Prothena Corp Public's Cash & Equivalents history runs 15 years deep, the most recent figure standing at $329.5 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 21.17% year-over-year to $329.5 million; the TTM figure through Mar 2026 stood at $329.5 million (down 21.17% YoY), while the FY2025 annual figure was $307.5 million, down 34.76% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $329.5 million, up from $307.5 million in the prior quarter.
- The five-year high for Cash & Equivalents was $710.4 million in Q4 2022, with the low at $307.5 million in Q4 2025.
- The 5-year median for Cash & Equivalents is $519.3 million (2024), against an average of $514.8 million.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents soared 58.31% in 2022, then tumbled 36.29% in 2025.
- Prothena Corp Public's Cash & Equivalents stood at $710.4 million in 2022, then fell by 12.89% to $618.8 million in 2023, then fell by 23.83% to $471.4 million in 2024, then slumped by 34.76% to $307.5 million in 2025, then grew by 7.13% to $329.5 million in 2026.
- Business Quant data shows PRTA's Cash & Equivalents at $329.5 million in Q1 2026, $307.5 million in Q4 2025, and $330.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - | 288.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 288.20 Mn |
| Mar 31, 2026 | 329.46 Mn |
| Dec 31, 2025 | 307.53 Mn |
| Sep 30, 2025 | 330.84 Mn |
| Jun 30, 2025 | 371.40 Mn |
| Mar 31, 2025 | 417.94 Mn |
| Dec 31, 2024 | 471.39 Mn |
| Sep 30, 2024 | 519.26 Mn |
| Jun 30, 2024 | 564.12 Mn |
| Mar 31, 2024 | 546.51 Mn |
| Dec 31, 2023 | 618.83 Mn |
| Sep 30, 2023 | 670.90 Mn |
| Jun 30, 2023 | 659.11 Mn |
| Mar 31, 2023 | 686.18 Mn |
| Dec 31, 2022 | 710.41 Mn |
| Sep 30, 2022 | 495.63 Mn |
| Jun 30, 2022 | 508.80 Mn |
| Mar 31, 2022 | 542.99 Mn |
| Dec 31, 2021 | 579.09 Mn |
| Sep 30, 2021 | 600.10 Mn |